TOCILIZUMAB , MK-1045 clinical trials

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma

This study is testing a new drug, MK-1045, alone or with other treatments, for Non-Hodgkin Lymphoma. Researchers want to see if it's safe and if it helps shrink the cancer. It includes both early safety tests and checking how well it works.